Een stuk van Investorshub over BIEL:
I've been watching biel for many years. They have been using shareholder's dollars on research and large but non profitable sales. With the successful launch this year in boots stores which is owned half by walgreens in the UK, they are finally about to make it big. They have 100s of doctors that approved these products in clinic documents and even politician endorsement. When this hits walgreens, they will make massive multi-year cycle sales. All they need to do is resubmit all the FDA docs that were declined in the past due to today's big news. When walgreens in the US hits, we are talking about an easy .50 pps IMHO. Products for humans and pets that are clinically proven, top of the line effective, non narcotic, and patented. I will buy many when they come to my local store. Go to the actipatch facebook and read the reviews about customers with chronic back pain and fibromayalga, they love the actipatch!
En het nieuwsbericht waarop de koers omhoog schoot:
Docket No. FDA-2012-N-0378
Filed 02/19/2014 at 8:45 am; Publication Date: 02/20/2014
SUMMARY: The Food and Drug Administration (FDA) is proposing to reclassify the shortwave diathermy (SWD) for all other uses, a preamendments class III device, into class II (special controls), and to rename the device "nonthermal shortwave therapy (SWT)." FDA is proposing this reclassification on its own initiative based on new information. FDA is also proposing a technical correction in the regulation for the carrier frequency for SWD and nonthermal SWT devices. This proposed action would implement certain regulatory requirements.
After considering available information, including the recommendations of the panel meeting on nonthermal SWT devices held on May 21, 2013, FDA has reevaluated the risks to health associated with the use of nonthermal SWT and made revisions from those previously identified in a proposed rule issued in the Federal Register on July 6, 2012 (77 FR 39953).
VI. Summary of Reasons for Reclassification
Based on the comments from the 2013 Panel meeting, the comments received in response to FDA's prior proposed rule (77 FR 39953, July 6, 2012), and FDA's assessment of new, valid scientific data related to the health benefits and risks associated with nonthermal SWT, FDA is proposing that these devices should be reclassified from class III to class II